Companies › Summit Therapeutics
1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Oncology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ivonescimab Dose 1 TIGIT inhibitor | TIGIT, CTLA4 | Phase 3 | Non-Small Cell Lung Cancer; Metastatic Urothelial Carcinoma | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06767514 | Ivonescimab Dose 1 | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Apr 2028 |
| NCT05899608 | Ivonescimab Dose 1 | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Dec 2028 |
| NCT07815665 | Ivonescimab Dose 1 | Phase 2 | Metastatic Urothelial Carcinoma | Oncology | Oct 2030 |
| NCT07815665 | Ivonescimab Dose 1 | Phase 2 | Metastatic Urothelial Carcinoma | Oncology | Oct 2030 |
Cash and short-term investments of $630m on 2026-09-30; operating cash outflow about $568m a year; runway about 13 months at that burn, to Nov 2027; 0 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
SynOx Therapeutics NingBo Junyan Hongshi Biosciences Taizhou Hanzhong biomedical InSightec Agenus
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.